Barclays Reiterates an 'Overweight' on Rigel Pharmaceuticals (RIGL); OSKIRA Trials on Track with OLE Data at ACR; Update on R343 Dev. Status Next
Tweet Send to a Friend
Barclays reiterates an 'Overweight' on Rigel Pharmaceuticals (NASDAQ: RIGL), PT $15.
Barclays analyst says, "We are maintaining our rating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are maintaining our rating on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
